{
    "clinical_study": {
        "@rank": "67091", 
        "arm_group": {
            "arm_group_label": "JUV\u00c9DERM VOLUMA\u00ae", 
            "arm_group_type": "Experimental", 
            "description": "Subjects treated with JUV\u00c9DERM VOLUMA\u00ae"
        }, 
        "brief_summary": {
            "textblock": "A prospective, open-label, observational study of the safety and efficacy of JUV\u00c9DERM\n      VOLUMA\u00ae to enhance the aesthetic appearance of the Asian nose"
        }, 
        "brief_title": "JUV\u00c9DERM VOLUMA\u00ae to Enhance the Appearance of the Asian Nose", 
        "completion_date": {
            "#text": "August 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Asian Nose Enhancement", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Asian subjects aged 20 years of age or older with dissatisfaction of their aesthetic\n             appearance due to structural features of their nose\n\n          -  Subjects who, in the opinion of the Investigator, can achieve a clinically meaningful\n             aesthetic correction of their nose with VOLUMA\u00ae treatment\n\n        Exclusion Criteria:\n\n          -  -Subjects requiring filler treatment in or around the tip of the nose or between the\n             eyebrows (glabellar region) to achieve a good aesthetic outcome\n\n          -  prior nasal surgery, including grafts, implants or filler injection to the nose area\n\n          -  Subjects with a history of sinusitis or rhinitis\n\n          -  Subjects unlikely to achieve a meaningful aesthetic result with the prescribed dosage\n             regimen of the study product.\n\n          -  Subjects receiving botulinum toxin treatment for any indication within 3 months of\n             the study or planning to receive botulinum toxin during the study\n\n          -  Subjects who have previously received aesthetic treatment in the forehead, glabellar,\n             and/or nose area with any dermal filler\n\n          -  Subjects with a history of any significant adverse events caused by dermal fillers\n\n          -  Subjects with a history of allergic responses to lidocaine or fillers\n\n          -  Subjects who are pregnant or breastfeeding or wish to become pregnant during the\n             study\n\n          -  Subjects of child-bearing age who are not prepared to practice an adequate form of\n             contraception during the course of the study\n\n          -  Subjects with traumatic scars in the treatment area or a history of active\n             inflammation, infection, cancerous lesion, or an unhealed wound in the treatment area\n\n          -  Subjects requiring dental or oral surgery, including dental implants, during the\n             study period\n\n          -  Subjects with a history of bleeding disorders\n\n          -  Subjects who are smokers\n\n          -  Subjects using blood thinning products within 10 days of the screening visit\n\n          -  Subjects with a history of connective tissue disease (e.g., rheumatoid arthritis,\n             lupus, scleroderma, etc) causing skin scarring\n\n          -  Subjects with a history of untreated epilepsy or other significant medical conditions\n\n          -  Subjects with a history of alcoholism or drug abuse of dependence\n\n          -  Subjects participating or likely to participate in another clinical trial within 30\n             days of screening or during the 1 year period of the study\n\n          -  Subjects with any other medical condition, which in the opinion of the Investigator,\n             might compromise the subject's ability to tolerate the injection procedure or comply\n             with requirements of the study"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "N/A", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "29", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "May 1, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01846039", 
            "org_study_id": "VOLXC-AP-ND-001"
        }, 
        "intervention": {
            "arm_group_label": "JUV\u00c9DERM VOLUMA\u00ae", 
            "description": "Up to 3 mL administered by intradermal injection", 
            "intervention_name": "Crosslinked hyaluronic acid gel", 
            "intervention_type": "Device", 
            "other_name": "JUV\u00c9DERM VOLUMA\u00ae"
        }, 
        "intervention_browse": {
            "mesh_term": "Hyaluronic Acid"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "December 23, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Sydney", 
                        "country": "Australia", 
                        "state": "New South Wales"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Gold Coast", 
                        "country": "Australia", 
                        "state": "Queensland"
                    }
                }
            }
        ], 
        "location_countries": {
            "country": "Australia"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Prospective, Open-label Study of the Safety and Efficacy of JUV\u00c9DERM VOLUMA\u00ae to Enhance the Aesthetic Appearance of the Asian Nose", 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": [
                "Australia: Therapeutic Goods Administration", 
                "Australia: Ethics Committee"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "September 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Assessment of Aesthetic Improvement Scale (AAIS)", 
            "safety_issue": "No", 
            "time_frame": "8 weeks"
        }, 
        "removed_countries": {
            "country": "Taiwan"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01846039"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Allergan Medical", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Allergan Medical", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}